Drug Trial Radar · NCT07921615
QLS4131 Plus Isa-V-CHOP in Newly Diagnosed, HIV-Negative PBL: A Single-Center, Single-Arm, Phase II Study
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Dec 9, 2027
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-center, single-arm, open-label, phase II exploratory clinical study designed to evaluate the efficacy and safety of QLS4131 combined with the Isa-V-CHOP regimen in patients with treatment-naive, HIV-negative plasmablastic lymphoma. The study plans to enroll 10 patients. The study consists of a screening period, a study treatment period, and a follow-up period. The screening period will last up to 21 days. The study treatment period will run from C1D1 to the end of Cycle 6, or until early termination due to disease progression, toxicity, or other reasons. After the end of study treatment, patients will be followed for 24 months.
Conditions
- Plasmablastic Lymphoma
Interventions
QLS4131 combined with Isa-V-CHOPDrug
This study uses QLS4131 combined with the Isa-V-CHOP regimen for a total of 6 study cycles, with each cycle lasting 21 days. Vincristine and bortezomib will be administered at the adjusted doses and frequencies listed below; the doses will not be routinely escalated to the original high-intensity regimen merely because of good early tolerability. The treatment components are as follows: QLS4131 + Isa + V-CHOP regimen QLS4131: C1, 0.6 mg on d1, 3 mg on d4, 12 mg on d8; C2-6, 12 mg on d1 Isatuximab: 10 mg/kg in C1 on d1 and d8; C2-6, on d1 Bortezomib: 1.3 mg/m², SC, on d1 and d8 Cyclophosphamide: 750 mg/m², IV, on d1 Doxorubicin: 40-50 mg/m² or liposomal doxorubicin 30-40 mg/m², IV, on d1 Vincristine: 1.0 mg/m² (maximum dose 1.5 mg), IV, on d1 Prednisone: 60 mg/m² (maximum dose 100 mg), d1-5
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete response rate (CRR)Time frame: 6 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.